Business Wire

Fossil Unveils Its Most Tech-Packed Touchscreen Smartwatch to Date

Del

It is with great excitement that Fossil brand announces its fourth generation of smartwatches under its Fossil Q line. With several new technology features, this new line provides consumers with the tech functionality they have been asking for in beautiful designs and styles they have come to expect from Fossil. With a robust list of new features, it is the brand's intent to provide customers with one all-inclusive device—both in function and design.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180806005100/en/

(Photo: Business Wire)

(Photo: Business Wire)

As one of the first fashion brands to introduce this level of technology to their collection, Fossil shows consumers you don’t have to sacrifice fashion for function. Powered with Wear OS by Google and the Qualcomm® Snapdragon Wear™ 2100 Platform, the new devices offer enhancements to every facet of the day, with hardware including Heart-Rate Tracking, NFC, Untethered GPS and Swimproof Functionality. Thanks to optimized charge time, users can now charge their device within an hour to last all day.

Fossil entered the smartwatch market to fill the growing desire for tech that was beautifully designed and could be personalized. This new generation is no different: it is packed with the unique design traits allowing users to customize from strap to dial. There are 36+ exclusive dials, from fashion forward to novelty dials, and users can integrate an increasing number of third party apps to their device experience, as well as set social media photos as watch face backgrounds. Fossil is continuing to design smartwatches as only Fossil can, with a vintage-inspired approach to modern technology that lets customers find a watch that perfectly suits their authentic selves.

‘’Since our entry to the smartwatch market, it has always been our first priority to be nimble and adapt quickly to innovations-both in technology and design’’ says Steve Evans, EVP of Fossil. “We know a lot of watch wearers have both a traditional watch and some kind of an activity tracker— by adding significant features in terms of technology, without compromising our design standards, this new generation of smartwatch will provide consumers with one device that fits all of their needs. Ensuring the best possible experience for our customers has always been important, which drove the innovation of this product; we cannot wait to see the consumer response around the globe.’’

Called Fossil Q Venture HR and Fossil Q Explorist HR, these devices can transition through all parts of daily life thanks to added functionality packed into fashionable designs. This new generation of smartwatches ushers in a more holistic user experience from a Fossil smartwatch with key features and personalization options that consumers care about.

Key updates include:

Heart-Rate Tracking:

Heart rate functionality was an important ask from consumers and a top priority for the Generation 4 Fossil Q line. Additionally, Fossil wanted to create exclusive watch dials that allowed users to easily access manual readings directly from their watch face. Whether going for a run outside or hitting the gym, you can automatically track your heart rate during logged exercises with Google Fit.

  • Take a manual heart rate reading and automatically track heart rate across multiple types of workouts using Google Fit
  • Heart rate graphs show progress throughout a large variety of workouts and improves workout tracking experience
  • Exclusive-to-Fossil dials have heart rate integrated into the designs, showing users their beats per minute on their watch face at a quick glance

NFC

NFC allows users to have payment and transit capabilities directly on their device. Exclusively compatible with Google Pay (transit and pay currently available in select countries), NFC prevents users from having to pull out their card every time they need to complete a transaction. With a few taps, your card is ready on watch to streamline any checkout experience. Security is an obvious consideration, and users set up a unique lock code on their watch to help protect from any identity or data theft.

Untethered GPS

New untethered GPS capabilities allow the users track walks, and runs, hikes, bike rides, and more via Google Fit and third-party fitness apps without having to bring your phone along. Your watch will automatically map and track your location and distance during logged workouts!

Thanks to added swimproof functionality, users can track swim workouts, hang poolside or hop in the shower without risk of damaging their smartwatch. For consumers ready to hit the trails for a run or ride without taking their phone, music can be downloaded from third party apps directly to device.

With this new generation of watch, Fossil is bringing a unique, fun take on technology. With function-based dials, social sharing abilities and an immense amount of personalization opportunities, these watches truly allows users to “Make it Your Own.” The added functions like Heart Rate, NFC, and GPS will give users a 360-holistic way to track all parts of their lives, while keeping true to the authentic creative spirit of innovative watch design that Fossil was founded on more than 30 years ago.

This watch retails for $255-$275.

Features include:

  • Stainless steel case (Q Venture HR: 40mm / Q Explorist HR: 45mm)
  • Stunning touchscreen digital display
  • 24+ hours battery life (based on usage)
  • Interchangeable straps and bracelets (Q Venture HR: 18mm / Q Explorist HR: 22mm)
  • Connect via Bluetooth® technology
  • Wireless syncing + magnetic charging
  • Compatible with iOS 9.3+ and Android 4.4+ (excluding Go edition)
  • Sensors: Heart Rate, NFC, GPS, Altimeter, Accelerometer, Gyroscope, Ambient Light, Microphone
  • Powered with Wear OS by Google
  • Qualcomm® Snapdragon Wear™ 2100 Platform

For more information, please visit www.fossil.com/Q.

LINK TO DOWNLOAD IMAGES

*The Google Assistant is not available in all languages. Android, Wear OS by Google, Google Play, Google Fit and other marks are trademarks of Google Inc.

Wear OS by Google and Android are trademarks of Google Inc.

Qualcomm, Snapdragon and Snapdragon Wear are trademarks of Qualcomm Incorporated, registered in the United States and other countries.

Qualcomm Snapdragon Wear is a product of Qualcomm Technologies, Inc. and/or its subsidiaries.

Contact information

Media Inquiries:
Gina Folin
GFolin@paulwilmot.com
or
Liza Backes
Lbackes@paulwilmot.com

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Incyte Announces Positive Interim Data from Phase 2 Trial of Pemigatinib, Its Selective FGFR Inhibitor, in Patients with Cholangiocarcinoma21.10.2018 10:45Pressemelding

Incyte Corporation (Nasdaq:INCY) announces updated data from its ongoing Phase 2 FIGHT-202 trial evaluating pemigatinib (INCB54828), its selective fibroblast growth factor receptor (FGFR) inhibitor, in patients with advanced/metastatic or surgically unresectable cholangiocarcinoma (bile duct cancer) who failed at least one previous treatment. In patients with FGFR2 translocations who were followed for at least eight months, interim study results demonstrated an overall response rate (ORR) of 40 percent, the primary endpoint, and a median progression free survival (PFS) of 9.2 months, a key secondary endpoint. These results are being presented at the European Society for Medical Oncology (ESMO) 2018 Congress in Munich, Germany in a poster presentation on Sunday, October 21 from 12:45 p.m. CEST to 1:45 p.m. CEST (6:45 a.m. ET to 7:45 a.m. ET). (Location: Hall A3 – Poster Area Networking Hub; Abstract #756P) “We are pleased to share updated interim results from our ongoing FIGHT-202 trial

Servier and Taiho Oncology Announce Phase III LONSURF® Study Has Met Primary and Secondary Endpoints Demonstrating Prolonged Overall Survival and Progression-Free Survival in Patients with Refractory Metastatic Gastric Cancer21.10.2018 09:10Pressemelding

Servier and Taiho Oncology, Inc. (U.S.), a subsidiary of Taiho Pharmaceutical Co., Ltd. (Japan), jointly announced today clinical data from the pivotal Phase III TAS-102 Gastric Study (TAGS) evaluating LONSURF® (trifluridine/tipiracil, TAS-102) versus placebo and best supportive care in patients with heavily pre-treated metastatic gastric cancer who have progressed or are intolerant to previous lines of therapy. The study met its primary endpoint of prolonged overall survival (OS) and secondary endpoint measures of progression-free survival (PFS) consistently supported the OS results, as well as continuing to demonstrate the predictable safety and tolerability profile of trifluridine/tipiracil. Data from TAGS was presented by Dr. Hendrik-Tobias Arkenau, Executive Medical Director of the Sarah Cannon Research Institute UK and an investigator for TAGS, at the ESMO 2018 Congress in Munich, Germany during an oral session (Abstract #LBA25). The study results were simultaneously published in

Phase 3 Data on Filgotinib in Biologic-Experienced Rheumatoid Arthritis to Be Presented at 2018 ACR/ARHP Annual Meeting20.10.2018 22:30Pressemelding

Gilead Sciences, Inc. (Nasdaq: GILD) and Galapagos NV (Euronext & NASDAQ: GLPG) today announced detailed results from the Phase 3 FINCH 2 clinical trial of filgotinib, an investigational, selective JAK1 inhibitor, in adults with moderately-to-severely active rheumatoid arthritis and prior inadequate response or intolerance to biologic agents. The data, which are being presented as a late-breaking poster at the 2018 American College of Rheumatology/Association of Rheumatology Health Professionals (ACR/ARHP) Annual Meeting in Chicago, suggest filgotinib has a potential role in addressing important unmet needs in the treatment of rheumatoid arthritis. Positive efficacy data from FINCH 2 were previously announced in September 2018. The data show statistically significant improvements in the proportion of patients achieving a range of clinical efficacy endpoints, including the proportion of patients achieving American College of Rheumatology 20 percent (ACR20, primary endpoint), 50 percent

Manchester United and True Religion Launch Denim Range19.10.2018 17:37Pressemelding

Manchester United (NYSE:MANU) and luxury denim brand True Religion have collaborated to launch a range of premium club branded denim wear. A first for the club, the new global partnership with the iconic American denim brand will see a range of men’s & women’s co-branded styles go on sale beginning 26th October in the club’s Megastore as well as online via United Direct and truereligion.com & eu.truereligion.com. The exclusive collection features jeans, shirts and jackets, including a highly desirable limited edition denim jacket embroidered with the club’s crest. Fans will have the opportunity to win a selection of clothing from the new range by visiting www.manutd.com/truereligion. Manchester United’s Group Managing Director, Richard Arnold, comments: “True Religion is a well-known, established name in fashion, creating unique designs without compromising on quality. The range we have collaborated on includes the same attention to detail and craftsmanship that has made True Religion

Arch Insurance Announces Strategic Leadership Changes19.10.2018 13:10Pressemelding

Arch Insurance today announced that Matt Shulman will assume the newly created role of CEO, Arch Insurance North America, effective January 1, 2019. In this role, he will lead Arch Insurance’s operations in the United States and Canada. He will report to Nicolas Papadopoulo, Chairman and CEO of Arch Worldwide Insurance Group. Mr. Shulman, who has more than 20 years of experience in the insurance industry, has been with Arch Insurance since 2009 and has served as the President and CEO of Arch Insurance Europe since 2016. “Matt brings significant U.S. and international experience to this role. Under his leadership, together with our senior team, Arch Insurance will continue to enhance our value proposition to our customers through a robust, diversified product portfolio, creative solutions and excellent service,” Mr. Papadopoulo said. Arch Insurance has also created a new organizational structure with three Chief Underwriting Officers (CUO) dedicated to specific lines of business. These

Takeda to Present Results from Phase 3 ALTA-1L Trial Highlighting Intracranial Efficacy of ALUNBRIG® (brigatinib) Versus Crizotinib in First-Line Advanced ALK+ Non-Small Cell Lung Cancer19.10.2018 12:00Pressemelding

Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that intracranial efficacy data from the Phase 3 ALTA-1L (ALK in Lung Cancer Trial of BrigAtinib in 1 st Line) trial showed improved intracranial progression-free survival (PFS) and intracranial objective response rate (ORR) with ALUNBRIG (brigatinib) compared to crizotinib among anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer (NSCLC) patients. Data for these secondary endpoints will be presented in a poster discussion at the European Society for Medical Oncology (ESMO) 2018 Congress on Friday, October 19 at 2:00 p.m. CET in Munich, Germany. These results further support ALUNBRIG as a potential treatment for adults with ALK+ locally advanced or metastatic NSCLC who had not received a prior ALK inhibitor. ALUNBRIG is currently not approved as first-line therapy for advanced ALK+ NSCLC. “ALK+ NSCLC often spreads to the brain, so having options that can clearly demonstrate efficacy both in the brain an